首页|西维来司他钠治疗急性呼吸窘迫综合征患者预后影响因素分析

西维来司他钠治疗急性呼吸窘迫综合征患者预后影响因素分析

扫码查看
目的 探讨西维来司他钠治疗急性呼吸窘迫综合征(ARDS)的效果及其预后影响因素。方法 选择2020年4月至2022年3月北京市大兴区人民医院ARDS患者160例,根据治疗方案不同分2组,各80例。对照组接受常规治疗,观察组在对照组基础上加用西维来司他钠。比较2组动脉血氧分压(PaO2)、二氧化碳分压(PaCO2)、氧合指数(PaO2/FiO2)及血清C反应蛋白(CRP)、降钙素原(PCT)水平变化。多因素Logistic回归分析影响西维来司他钠治疗ARDS预后的因素。结果 治疗后观察组PaCO2及血清CRP、PCT水平较对照组低,PaO2、PaO2/FiO2较对照组高(P<0。05);观察组死亡患者年龄>60岁比例、基线急性生理学与慢性健康状况评分Ⅱ(APACHE Ⅱ)高于存活患者,发病距入院时间长于存活患者,红细胞体积分布宽度(RDW)大于存活患者(P<0。05);多因素Logistic回归分析,年龄、呼气终末正压(PEEP)水平、基线APACHE Ⅱ评分、发病距入院时间、RDW水平与西维来司他钠治疗ARDS预后有关(P<0。05)。结论 西维来司他钠治疗ARDS能有效减轻炎症,改善血气指标,但仍具有较高预后不良风险,其影响因素包括年龄、发病距入院时间、基线APACHE Ⅱ评分、RDW水平等,积极监测上述指标对提高ARDS救治成功率及预后改善有重要意义。
Influencing factors on prognosis of patients with acute respiratory distress syndrome treated with sivelestat sodium
Objective To investigate the efficacy and prognostic factors of sivelestat sodium in the treat-ment of acute respiratory distress syndrome (ARDS). Methods A total of 160 ARDS patients admitted to Daxing District People's Hospital in Beijing from April 2020 to March 2022 were divided into a control group and an ob-servation group based on different treatment plans,with 80 cases in each group. The control group received con-ventional treatment,while the observation group received sivelestat sodium in addition to the same treatment as the control group. The changes in arterial partial pressure of oxygen (PaO2),partial pressure of carbon dioxide (PaCO2),oxygenation index (PaO2/FiO2),and serum levels of C-reactive protein (CRP) and procalcitonin (PCT) were com-pared between the two groups. The factors affecting the prognosis of ARDS treated with sivelestat sodium were an-alyzed using Logistic regression. Results After treatment,the levels of PaCO2,CRP and PCT in the observation group were significantly lower than those in the control group,while PaO2 and PaO2/FiO2 were significantly higher than those in the control group (P<0.05). The proportion of dead patients aged>60 years old and baseline A-PACHE Ⅱ score in observation group were higher than those in survival patients,the time between onset and ad-mission was longer than that in survival patients,and the volume distribution width of red blood cells (RDW) was larger than that in survival patients (P<0.05). Logistic regression analysis showed that age,PEEP level,baseline APACHE Ⅱscore,onset time to hospital admission and RDW level were correlated with the prognosis of ARDS treated with cilvelestat sodium (P<0.05). Conclusion Sivelestat sodium can effectively reduce inflammation and improve blood gas indicators in the treatment of ARDS,but still has a high risk of poor prognosis. Its influencing factors include age,time from onset to admission,baseline APACHE Ⅱ score,RDW level,etc. Actively monitoring these indica-tors has important guiding value for improving the success rate of ARDS treatment and prognosis improvement.

Respiratory distress syndromeSivelestat sodiumRoot cause analysis

王瑾、周冠华、王助衡

展开 >

北京市大兴区人民医院ICU,北京 102600

呼吸窘迫综合征 西维来司他钠 影响因素分析

2024

中国药物与临床
中国医院协会

中国药物与临床

影响因子:0.846
ISSN:1671-2560
年,卷(期):2024.24(22)